This feature of YCH337 is likely to open the door for the dual tubulin/Top2 targeting strategy for cancer therapy due to extensive clinical uses of tubulin inhibitors in combination with Top2 inhibitors and frequent emergence of drug resistance to them. This evidence concerns the gene TOP2A and cancer.